(Q36717359)

15 August 2017

1 reference

title

Cetuximab in the treatment of metastatic colorectal cancer (English)

1 reference

15 August 2017

1 reference

1 reference

Nicolas Moosmann

1

1 reference

15 August 2017

Volker Heinemann

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

243-256

1 reference

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

The epidermal growth factor receptor mediates radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Diffusely infiltrative low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Preoperative versus postoperative chemoradiotherapy for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Breaking bad news: learning through experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cetuximab therapy and symptomatic hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.2.243

21 January 2018

Identifiers

DOI

10.1517/14712598.7.2.243

1 reference

15 August 2017

1 reference